| [infection/immunity by hepatitis b virus in an adult population of havana city. cuba 1995]. | the results of a study of markers of infection/immunity by hepatitis b virus in a community of the health area in "cristobal labra" polyclinics, city of habana in 1995. the studied healthy adult population was not included in any vaccination strategy with hepatitis b vaccine. two markers were studied: hepatitis b surface antigen and its corresponding antibody (anti-hbs). hbsag-positivity was 1.05% and anti-hbs positivity was 13.39%. of anti-hbs-positive cases, 13.39% had titers from 10-50 ui/l a ... | 1999 | 10887591 |
| [impact of an anti-hepatitis b virus (hbv) immunization program in patients undergoing dialysis in havana, cuba]. | the follow-up of hbv markers in selected high infection risk populations, in patients from the hemodialysis and peritoneal dialysis services was used to assess the effectiveness of a special vaccination program. viral infection markers were studied in prevalence cross sections of the whole population of patients, and also by recording the reports of clinical cases of hepatitis b occurred during that period in those groups of patients. the prevention program consisted of the vaccination of all pa ... | 2000 | 11155765 |
| [prevalence of hepatitis b virus markers and risk factors associated in haemodialysis patients from havana city; 2002-2003]. | | 2007 | 17564577 |
| hepatitis c virus antibodies and other markers of blood-transfusion-transmitted infection in multi-transfused cuban patients. | hcv was initially identified in 1989 when it was found to be the primary causative agent of non-a, non-b hepatitis,a condition associated with high rates of progressive and end-stage liver disease, cirrhosis, and hepatocellular carcinoma. since then, appreciation of the significant worldwide health impact of hcv infection has grown. hcv infection was identified as a public health problem in cuba in the 1990s. despite universal blood donor screening, which was achieved in 1995 using the cuban imm ... | 2005 | 16461239 |
| [the immunogenicity of the heberbiovac-hb vaccine in the elderly]. | the cuban recombinant vaccine against the hepatitis b virus was applied to a group of individuals over 65 from a geriatric home in havana city. dose of 20 ìg were administered within a scheme from 0.1 to 6 months in order to study its immunogenicity, which was evaluated at 2, 7, and 12 months after the first dose. 47.1% of protective titres and geometrical mean of 6.04 ui/l were obtained after 60 days. 100% of seroconversion (ui/l) and seroprotection (10 ui/l) and geometric mean of 136.93 ui/l w ... | 1996 | 9805052 |